login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
JAZZ PHARMACEUTICALS PLC (JAZZ) Stock News
USA
-
Nasdaq
- NASDAQ:JAZZ -
IE00B4Q5ZN47
-
Common Stock
176.92
USD
-3.13 (-1.74%)
Last: 11/26/2025, 8:00:02 PM
176.92
USD
0 (0%)
After Hours:
11/26/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
JAZZ Latest News, Press Relases and Analysis
All
Press Releases
10 days ago - By: Chartmill
- Mentions:
TAIT
SSP
CANG
RPTX
...
The market is filled with gapping stocks in Monday's session.
17 hours ago - By: Zacks Investment Research
- Mentions:
TLRY
VRNO
Why Jazz Pharmaceuticals May Be a Stealth Cannabis Winner
8 days ago - By: Jazz Pharmaceuticals plc
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
9 days ago - By: Zacks Investment Research
- Mentions:
ALKS
CRMD
ZYME
JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data
10 days ago - By: Zacks Investment Research
Why Jazz (JAZZ) International Revenue Trends Deserve Your Attention
10 days ago - By: Investor's Business Daily
- Mentions:
ZYME
Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer
10 days ago - By: Jazz Pharmaceuticals plc
Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera® (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal
16 days ago - By: Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso™ (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025
21 days ago - By: Zacks Investment Research
- Mentions:
ALKS
ANIP
CRMD
JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View
21 days ago - By: The Motley Fool
Jazz Pharma (JAZZ) Earnings Call Transcript
21 days ago - By: Zacks Investment Research
Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
21 days ago - By: Zacks Investment Research
- Mentions:
IFRX
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Beat Estimates
21 days ago - By: Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance
22 days ago - By: Benzinga
- Mentions:
TECH
INSE
GEF
SKYT
...
Earnings Scheduled For November 5, 2025
23 days ago - By: Benzinga
Insights into Jazz Pharmaceuticals's Upcoming Earnings
23 days ago - By: Zacks Investment Research
- Mentions:
ANIP
AXSM
NTLA
AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales
a month ago - By: Zacks Investment Research
- Mentions:
HRMY
Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q3 Earnings Expected to Decline
a month ago - By: Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors
a month ago - By: Jazz Pharmaceuticals plc
Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025
Please enable JavaScript to continue using this application.